Background: Metabolic syndrome/epicardial adipose tissue (EAT) plays an important
| INTRODUCTION
Pulmonary vein isolation (PVI) is a widely accepted therapeutic option for symptomatic atrial fibrillation (AF). 1 Despite advances in ablation technologies and strategies, some patients suffer AF recurrence due to pulmonary vein (PV) reconnections or to non-PV triggers. Another contributor to AF recurrence is atrial remodeling as manifested by atrial dilatation or fibrosis. 2 Maintenance of sinus rhythm after successful PVI leads to a reduction in left atrial volume (LAV), so-called reverse atrial remodeling (RAR). Although RAR is clearly associated with long-term maintenance of sinus rhythm 3 , the mechanism responsible for RAR that occurs after ablation remains uncertain. Clarifying the mechanism underlying RAR after ablation may be beneficial in terms of patient management after AF ablation.
Metabolic syndrome, which refers to a group of risk factors for cardiovascular disease, such as obesity, hypertension, and dyslipidemia, plus high blood sugar is one of several modifiable risk factors for AF. [4] [5] [6] [7] [8] [9] [10] Patients such as those with metabolic syndrome tend to have increased visceral fat. [11] [12] [13] Pericardial adipose tissue is a type of visceral fat that consists of paracardial fat located outside the parietal pericardium and epicardial fat/epicardial adipose tissue (EAT)
between the visceral pericardium and the myocardium. EAT in particular has emerged as an important factor in the pathogenesis of metabolic syndrome, and it has also been linked to the progression of AF. [14] [15] [16] We hypothesized that EAT and the presence of metabolic syndrome may impede RAR and sinus rhythm maintenance after ablation. EAT is often assessed by mean of computed tomography (CT)-or magnetic resonance imaging (MRI)-based measurement 17 , but such measurement, performed with the use of specific offline software is burdensome. Transthoracic echocardiography (TTE) is generally used in the management of AF, and it can be used to determine EAT thickness simply and noninvasively. Several reported studies have shown that TTE-determined EAT thickness, defined by the echo-free space between the right ventricle and pericardium, correlates strongly with that measured on CT images and that it is strongly associated with ablation outcome as well as the postablation recurrence of AF. 18, 19 We, in the study described herein, explored the effects of TTE-measured EAT and metabolic syndrome on RAR and ablation outcome.
| ME TH ODS

| Study design
Included in the study were 104 consecutive patients (75 men, 29
women, aged 63 ± 10 years) who underwent ablation for AF between June 2015 and November 2016. In all 104 patients, TTE was performed 1 day before ablation and 3, 6, and 12 months after ablation. The study protocol was approved by the institutional review board of Nihon University Itabashi Hospital (Approval no:
RK-180213-12; Approval date: February 14, 2018). All patients provided written informed consent for the electrophysiologic study, ablation procedure, and use of their anonymized data for study purposes. Adequate oral anticoagulation was given for at least 1 month prior to the ablation procedure, and all antiarrhythmic drugs were stopped for at least 5 half-lives prior to the procedure.
| Blood chemistry tests
Cardiac catheterization was performed in preparation for the ablation procedure, and blood samples were drawn from the patient's jugular vein via the sheath placed for the coronary sinus catheter. The blood samples were obtained for evaluation of serum high-sensitivity C-reactive protein (hs-CRP), which was measured by particle-enhanced immunonephelometry (BN II System, Siemens Healthcare Diagnostics
Inc., Marburg, Germany), and serum N-terminal pro-brain natriuretic peptide (NT-proBNP), which was measured by sandwich chemiluminescent enzyme immunoassay (Roche Diagnostics., Mannheim, Germany).
| Ablation procedure
PVI was performed by using contact force (CF)-based ablation or cryoballoon ablation (CBA) under sedation induced with intravenous propofol and fentanyl, as previously reported. 20 In brief, vascular access was obtained through the right internal jugular vein and both femoral veins. A 14-pole catheter (7 4-mm proximal electrodes, 2-mm spacing; The details of the measurement have been described in our previous publication. 16 
| Data collection
Clinical data, laboratory data immediately before the ablation procedure, and echocardiographic variables were obtained 1 day T A B L E 1 Clinical characteristics and laboratory, echocardiographic, and catheterization data for the total patients and per patients in whom reverse atrial remodeling did and did not occur 
| Postablation follow-up
After ablation, all patients were followed-up regularly at 1, 3, 6 , and every 6 months thereafter at the outpatient clinic. Routine electrocardiography (ECG) was performed at each visit, and 24-hour Holter monitoring was scheduled to follow the 6-and 12-month follow-up visits. A blanking period of 3 months was established, and recurrence of AF was defined as any ECG recording of AF or any Holter recording of AF lasting more than 30 seconds.
| Statistical analysis
Continuous variables are expressed as mean ± SD, with the exception of follow-up time, duration of AF, and biomarkers levels, which are expressed as median values and interquartile ranges. Variables were compared between patients in whom RAR developed and patients in whom RAR did not develop or between patients in whom AF recurred and those in whom it did not recur, and differences in continuous variables were analyzed by 2-tailed t test or Mann-Whitney U test. Categorical variables are expressed as percentages, and 
| RESULTS
| Patient characteristics
Clinical characteristics of the total patients and of those with and without RAR are summarized in Table 1 . Seventy-five (72%) patients were male, and patients' mean age was 63 ± 10 years. Mean body mass index (BMI) was 23. 
| Reproducibility and validation of TTE-based EAT measurements
Bland-Altman plots revealed no interobserver or intraobserver difference across the range of measurements (mean bias of 0.19 with 95% F I G U R E 2 Changes in epicardial adipose tissue and body weight after ablation in the AF nonrecurrence group and AF recurrence group. AF, atrial fibrillation . The TTE-derived EAT thickness correlated moderately with the total EAT volume (r = 0.6741, P < 0.001) and peri-LA EAT volume (r = 0.6387, P < 0.001).
| Characteristics of patients with and without
RAR and major determinants of RAR
As shown in Table 1 , metabolic syndrome was more prevalent among patients without RAR than among those with RAR (62% vs.
28%, respectively; P = 0.0006). The baseline LAV index was significantly lower in patients without RAR than in those with RAR (24.6 ± 7.5 mL/m 2 vs. 28.8 ± 10.6 mL/m 2 , respectively; P = 0.0233).
Representative transthoracic echocardiograms from patients with and without RAR are shown in Figure 1A and B. EAT was significantly thicker in patients without RAR than in those with RAR Table 2) .
| Influence of RAR on ablation outcome
During the median follow-up period of 658 (373-803) days, the AF recurred in 23 (22%) of the 104 patients. Clinical characteristics and laboratory and echocardiographic variables of patients with and without AF recurrence are summarized in Table 3 . EAT was signifi- After the 12-month follow-up period, EAT thickness had decreased significantly from 4.17 ± 1.16 mm to 3.65 ± 1.16 mm in the AF nonrecurrence group (P < 0.0001), but there was not a significant change in thickness in the AF recurrence group (from 5.05 ± 2.19 mm to 4.73 ± 2.16 mm, P = 0.1892) (Figures 2 and 3 ).
There was not a significant change in body weight during the followup period in either group (AF nonrecurrence group: from 65.8 ± 12.4 kg to 65.7 ± 12.5 kg, P = 0.6223; AF recurrence group: from 67.9 ± 14.0 kg to 68.0 ± 14.0 kg, P = 0.8569). No significant correlation was observed between the reduction in the LAV index and reduction in the EAT thickness (r = −0.1778, P = 0.0710).
| DISCUSSION
This study yielded three major findings: (1) independent association between metabolic syndrome and thick EAT and absence of RAR after ablation for AF, (2) significant association between postablation AF recurrence and thick EAT, and (3) association between AF ablation success and a significant reduction in the EAT thickness 12 months after ablation.
| Mechanism of RAR after AF ablation
As noted above, we found the LAV index to be decreased 3 months after ablation, and RAR was observed in 55% of the total patients. It is well known that AF ablation effectively reverses left atrial remodeling. Reported studies have shown age, hypertension, persistent AF, and a long P wave duration to be major hindrances to decreased LAV after ablation. 25, 26 Our study results added to the findings of the previous studies regarding mechanistic insight into the absence of RAR after ablation. Among our study patients, metabolic syndrome and thick EAT were independently associated with the absence of RAR after AF ablation. Metabolic syndrome and EAT have been linked to the presence and progression of AF. 16, 27 Increased EAT may be a manifestation of metabolic syndrome, as are obesity, hypertension, high blood sugar, and dyslipidemia, four factors that are strongly associated with left atrial remodeling. [4] [5] [6] [7] [8] [9] [10] 28 Further, an increased EAT itself may lead directly to atrial remodeling by the effects of bioactive free fatty acid and a number of other bioactive molecules, such as adiponectin, resistin, and inflammatory cytokines, and by the effect of ganglionated plexi (GP). [14] [15] [16] [17] These multiple mechanisms underlying EAT-promoted left atrial remodeling modestly persist even after the ablation. 22, 27 We speculated that substrates responsible for AF in patients with metabolic syndrome and EAT-based vulnerability to AF may ultimately surpass the favorable effects of ablation, attenuating the effect of RAR.
| Influence of EAT on ablation outcome
That maintenance of sinus rhythm after AF ablation led to a reduction in the EAT thickness in our patients, especially in those in whom AF did not recur, was a novel finding. Reduction in EAT has been reported MONNO ET AL.
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to accompany weight loss 29 , and studies have shown that liraglutide (an analog of glucagon-like peptide-1), sitagliptin (dipeptidyl peptidase-4 inhibitor), and dapagliflozin (sodium-glucose co-transporter-2) reduce EAT in patients with type 2 DM. [30] [31] [32] In our study patients, EAT decreased after ablation despite absence of weight loss. Therefore, our results support the notion that EAT is derived from AF, although previous reports have suggested EAT as the cause of AF. [14] [15] [16] [17] There are several suggested explanations for the reduction in EAT that follows AF ablation. EAT is considered to release free fatty acids (FFAs) as energy to the myocardium in a state of a high metabolic demand. 33 Animal studies have shown that the atrial oxygen consumption and coronary flow increase almost threefold after the induction of AF and lead to contractile dysfunction. 34, 35 Therefore, it is possible that the greater fat depots around the LA in AF patients would be accompanied by a decreased reservoir function through augmented LA kinetic energy and the ejection force. In fact, it has been suggested that regional adipose tissues can be beneficial by preserving myocardial energy supply under certain circumstances, yet simultaneously impose certain negative effects generated by the inflammatory process. 36 Conversely, the maintenance of sinus rhythm after ablation improves the atrial contractile function, and reduces the atrial oxygen consumption and coronary flow. These myocardial conditions would decrease the LA myocardium's energy supply and negative effects of the inflammatory process. In fact, we reported postablation decreases in the levels of inflammatory and fibrotic markers such as hs-CRP, IL-6, and matrix metalloproteinase-2. 37 In addition, endocardial ablation of EAT appears to abolish GP activity and improve ablation outcomes. 27 The maintenance of sinus rhythm by ablation may decrease the myocardium's energy supply, local levels of these biomarkers, and/or GP activity, in turn attenuating the 
| Metabolic syndrome/obesity and ablation outcome
We found a strong association between metabolic syndrome and the absence of RAR after ablation, but we found no association between metabolic syndrome and postablation AF recurrence.
Whether being overweight and obesity can lead to a poor outcome after AF ablation remains controversial. Reported studies showed association between body weight >200 lbs or BMI ≥25 kg/m 2 and AF recurrence beyond 12 months. 38, 39 In contrast, other reported studies showed BMI not to be predictive of AF recurrence after the blanking period. 40, 41 One of the reasons for the contradictory results may be the difference between the studies in the proportion of overweight or obese patients. In the former two studies, the mean BMI was high and being overweight and obesity were quite prevalent, whereas in the latter two studies, the mean BMI was low, and the prevalence of being overweight and obesity was also low. The BMI in our study patients was relatively low (median:
23.9 kg/m 2 ), which may have obscured the association between metabolic syndrome and a poor ablation outcome. Another factor at play in our study was the furtherance of the ablation technology. Ablation modalities such as CF-based radiofrequency ablation and balloon-based ablation have improved the ablation efficacy.
These technologies may minimize the effect of metabolic syndrome in leading to an AF recurrence. Nevertheless, our results indicated that the EAT was significantly thicker, and absence of RAR tended to be more prevalent in patients with postablation AF recurrences than in those without. Therefore, EAT or the absence of RAR can be a better reflection of vulnerability predisposing to AF recurrence than metabolic syndrome/obesity. Metabolic syndrome was recently shown to be an independent predictor of a delayed postablation recurrence of AF, ie, recurrence 2 years after ablation. 42 Taken together, a study that includes a very large patient group and long follow-up period may be needed to clarify this issue.
| Limitations
Our findings should be interpreted in light of our study limitations.
The study was limited in size to 104 patients. Despite a relatively small number of patients, a thick EAT was strongly associated with the short-term effect (absence of RAR) and long-term outcome after ablation, but metabolic syndrome was only related to the short-term effect. These findings implicate a better predictive role of EAT on AF vulnerability than that of metabolic syndrome. In addition, EAT was not assessed by 3D CT images at 12 months after the procedure because of no patient benefit when considering the radiation exposure from the CT scan. Nonetheless, the EAT thickness measured echocardiographically has been reported to be significantly correlated with the EAT volume measured by multislice CT, 18, 19 and we could also find a significant correlation of the EAT thickness with the total/peri-LA EAT volume before ablation.
| CONCLUSION S
In patients who underwent AF ablation, an increased EAT and presence of metabolic syndrome were independently associated with the absence of RAR. The postablation AF recurrence was significantly associated with an increased EAT, but not with metabolic syndrome. The EAT thickness decreased significantly after ablation, especially in patients for whom ablation was successful. Our data suggest that EAT may confer vulnerability to AF even after AF ablation, but that an EAT reduction has a favorable effect on the ablation outcome.
